about
Pharmacogenetics of treatment response in psoriatic arthritisGenotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practiceDrug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.The safety of biologic therapies in RA-associated interstitial lung disease.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Building the future of rheumatology: the role of national and international networks.Primary percutaneous coronary intervention for acute ST elevation myocardial infarction--first year's experience of a tertiary referral centre in the UK.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET).Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis.Annual increase in body mass index in children with asthma on higher doses of inhaled steroids.'Twitterland': a brave new world?Opioids are not just an American problem.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Abatacept in the long-term treatment of rheumatoid arthritis.Unilateral breast oedema in a case of non-rheumatic giant left atrium.Frequent discussion of insomnia and weight gain with glucocorticoid therapy: an analysis of Twitter postsPrediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximabEffectiveness of switching between biologics in psoriatic arthritis- results of a large regional surveyThe Genetics of Psoriasis and Psoriatic ArthritisImpact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid ArthritisLatent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs
P50
Q28081252-606E9380-0426-4E47-B5B0-464F87D842BEQ35752908-8C79FD64-FBF1-4F37-9A96-B65D8CC57B12Q36832755-D05C4C47-7521-403F-93DC-9C0C7FBB5CF0Q37383419-195688B9-D8D2-41D4-9041-9844BADD9226Q37484873-C3874EAA-3D50-46BF-B2B2-D9B7C40DFC7FQ37599165-F37241EA-B4D7-40A0-B4C3-E1C8E6A203F9Q37604498-F00DFBF7-79DA-4C96-A873-F6F21A66BFADQ38129037-D625DF2E-F1A2-4620-8D2D-9A8EFD52FCD4Q38173669-F76D0CC0-2AE0-40FE-80A1-EB29E3F16E0EQ38642378-FBE830FA-DA3A-424F-BE91-7C8BAC6D9629Q38740273-7F79AB50-4850-4A97-BEC7-A47DC17A52CFQ39853191-22235651-E915-4A14-85CF-EC49734F8741Q40305889-3DB2093F-3819-4D50-9500-53CFCCF29165Q40503531-F5747420-7E2D-495E-AEF7-BBA7653B4F82Q41447431-7C785DCB-6EB9-4B98-B0CD-F5BD7A51D540Q46754978-136E70E4-3AFB-44D7-83F2-43E99A55CC6DQ47587722-8890F6FD-7F40-48DD-B63C-459335E9230EQ50046141-83F3A63D-1098-486B-9CAB-6DDBBE5284B9Q50083992-246B649A-02A5-4D28-918E-3CA58200017FQ52622604-05B22353-CF33-4DC4-9143-AC66901B89B2Q53344658-4042FA5D-17BB-4D0B-A854-08FFC6042EE8Q59282383-755ECCAF-C8E6-4AED-8763-C42EF6A6AB28Q64075736-5136815C-1AD0-4304-ACC8-6C6E08269BD6Q84434499-1501E4E4-341D-42BD-B2B7-42F763C2D2FAQ87302920-BD917A34-8644-41A1-A4EF-D87045F62F4AQ92465788-C18D880B-DC2B-4905-B5B0-11F020712999Q92730489-3E7A6FCD-D892-4415-A8E0-5538A1FC263CQ96016711-3C21D0CF-8963-47AE-B793-661D97FDEA4D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Meghna Jani
@ast
Meghna Jani
@en
Meghna Jani
@es
Meghna Jani
@nl
Meghna Jani
@sl
type
label
Meghna Jani
@ast
Meghna Jani
@en
Meghna Jani
@es
Meghna Jani
@nl
Meghna Jani
@sl
prefLabel
Meghna Jani
@ast
Meghna Jani
@en
Meghna Jani
@es
Meghna Jani
@nl
Meghna Jani
@sl
P106
P1153
53979750000
P31
P496
0000-0002-1487-277X